NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...
The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
For people with AD, Johnson & Johnson's research offers hope ... “Many patients with AD have higher rates of depression, anxiety, stress and suicide,” she says. Existing treatments for AD ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to help ...